Ep. 254, Chapter 4: LNP Progress & Regulation with Michelle Werner

42:16 -END

Alltrna's lead candidate for genetic diseases utilizes a lipid nanoparticle (LNP) for liver delivery and is currently in IND-enabling studies. LNPs being well-characterized and commercially available allows Alltrna to focus on the novel tRNA payload's safety and efficacy, rather than delivery. Alltrna also is engaging with health authorities to pave the way for its basket trial strategy, which aligns with regulators' stated interest in "many diseases at a time" approaches to address the vast unmet need. Moving forward, Werner says Alltrna's main challenge is transitioning from a research-focused company to one equally weighted in R&D, building clinical capabilities, and securing capital to advance its technology.